CD117-positive ovarian cancer: a literature review
https://doi.org/10.31549/2542-1174-2025-9-2-83-96
Abstract
I n t r o d u c t i o n . Ovarian cancer is one of the most aggressive malignant tumors of the female reproductive system, characterized by high mortality and difficulty in early detection. At the early stages, ovarian cancer is usually asymptomatic, which complicates its diagnosis until the disease reaches advanced clinical stages.
A i m . To demonstrate the clinical, morphological and prognostic features of ovarian cancer with CD117 expression.
M a t e r i a l s a n d m e t h o d s . An analysis of various literature sources considering the problem of ovarian cancer associated with CD117 expression was performed. PubMed, Scopus, Research Square and Web of Science databases were used to search for literature. The review includes articles published from 2021 to 2024.
R e s u l t s . The analysis of the literature data confirmed the presence of high CD117 expression in tumor cells in combination with other immunohistochemical markers characteristic of high-grade serous ovarian cancer (SOX2, COT4, and NANOG). CD117 activation in ovarian cancer leads to activation of downstream signaling pathways involving the genes: RAS/ERK, PI3K, SRC, JAK/STAT, Wnt, and Notch, resulting in the formation of cancer stem cell populations, which determines high aggressiveness of the tumor.
C o n c l u s i o n . High expression of CD117 is associated with poor prognosis, more aggressive disease progression and tendency to metastasizing.
About the Authors
D. V. Bulanov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Dmitriy V. Bulanov – Cand. Sci. (Med.), Pathologist, Associate Professor, Department of Pathological Anatomy and Clinical Pathological Anatomy, Institute of Human Biology and Pathology
Author ID: 1102049
Scopus Author ID: 57189492346
Web of Science Researcher ID: KVY-3412-2024
bld. 6, 1, Ostrovityanova str., Moscow, 117513
A. M. Soloveva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Anna M. Soloveva – Student, Medical Faculty
bld. 6, 1, Ostrovityanova str., Moscow, 117513
References
1. Frąszczak K., Barczyński B. The role of cancer stem cell markers in ovarian cancer// Cancers. 2023;16(1):40. DOI: 10.3390/cancers16010040.
2. Sheleby M.H., Sanoh N.E., Gad M.S. et al. Circulating tumor cells in ovarian cancer patients as a cellular marker for early detection of ovarian cancer in asymptomatic patients// Research Square. 2023. DOI: 10.21203/rs.3.rs-2348042/v1.
3. Shnaider P.V., Petrushanko I.Yu., Aleshikova O.I. et al. Expression level of CD117 (KIT) on ovarian cancer extracellular vesicles correlates with tumor aggressiveness// Front. Cell Dev. Biol. 2023;11:1057484. DOI: 10.3389/fcell.2023.1057484.
4. Al-Shami S.A., Al-Kaabi M.M., Mahdi A.K., Al-Attar Z. Immunohistochemical expression of CD117 in borderline, low- and high-grade ovarian surface epithelial tumours: A clinicopathological study// Malays. J. Pathol. 2023;45(2):229-236.
5. Mallon H.E., Ramírez G.A., Dolenšek T. et al. CD117 expression in canine ovarian tumours// J. Comp. Pathol. 2024;212:1-5. DOI: 10.1016/j.jcpa.2024.05.001.
6. Li Z., Li Y., Bai J. et al. Integrated analysis of ovarian cancer stem cells-associated lncRNA-miRNA-mRNA network via microarray and Gene Expression Omnibus database// Research Square. 2022. DOI: 10.21203/rs.3.rs-2221089/v1.
7. Bååth M., Jönsson J.M., Westbom Fremer S. et al. MET expression and cancer stem cell networks impact outcome in high-grade serous ovarian cancer// Genes(Basel); 2021;12(5):742. DOI: 10.3390/genes12050742.
8. Berek J.S., Renz M., Kehoe S. et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update// Int. J. Gynaecol. Obstet. 2021;155 Suppl 1(Suppl 1):61-85. DOI: 10.1002/ijgo.13878.
9. Fan Y., Cheng H., Liu Y. et al. Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells// Front. Pharmacol. 2022;13:955984. DOI: 10.3389/fphar.2022.955984.
10. Wang J., Ford J.C., Mitra A.K. Defining the role of metastasis-initiating cells in promoting carcinogenesis in ovarian cancer// Biology (Basel). 2023;12(12):1492. DOI: 10.3390/biology12121492.
11. Xu H., Zhao F., Wu D. et al. Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination// Biomed. Pharmacother. 2023;161:114547. DOI: 10.1016/j.biopha.2023.114547.
12. Wang K., Liu S., Dou Z. et al. Loss of Krüppel-like factor 9 facilitates stemness in ovarian cancer ascitesderived multicellular spheroids via Notch1/slug signaling// Cancer Sci. 2021;112(10):4220-4233. DOI: 10.1111/cas.15100.
13. Yan B., Mu Y., Cui M., Liu L. Clinicopathological significance and prognostic implication of CD44 and its splice variants (v3 and v6) in colorectal cancer// Transl. Cancer Res. 2020;9(2):1215-1224. DOI: 10.21037/tcr.2020.02.12.
14. Ho C.M., Lee F.K., Yen T.L. et al. Everolimus combined with 5-aza-2-deoxycytidine generated potent antitumor effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway// Am. J. Cancer Res. 2022;12(4):1686-1706.
15. Li J., Hou Y., Ding H. et al. 1α,25-hydroxyvitamin D/ VDR suppresses stem-like properties of ovarian cancer cells by restraining nuclear translocation of β-catenin// Steroids. 2024;211:109488. DOI: 10.1016/j.steroids.2024.109488.
16. Vitale D.L., Parnigoni A., Viola M. et al. Deciphering drug resistance: Investigating the emerging role of hyaluronan metabolism and signaling and tumor extracellular matrix in cancer chemotherapy// Int. J. Mol. Sci. 2024;25(14):7607. DOI: 10.3390/ijms25147607.
17. Yu H., Wang J., Wu B. et al. Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis// J. Ovarian Res. 2023;16(1):28. DOI: 10.1186/s13048-023-01102-8.
18. Iżycka N., Zaborowski M.P., Ciecierski Ł. et al. Cancer stem cell markers–Clinical relevance and prognostic value in high-grade serous ovarian cancer (HGSOC) based on The Cancer Genome Atlas analysis// Int. J. Mol. Sci. 2023;24(16):12746. DOI: 10.3390/ijms241612746.
19. Izycka N., Rucinski M., Andrzejewska M. et al. The prognostic value of cancer stem cell markers (CSCs) expression–ALDH1A1, CD133, CD44–for survival and long-term follow-up of ovarian cancer patients// Int. J. Mol. Sci. 2023;24(3):2400. DOI: 10.3390/ijms24032400.
20. Cruz L.S., Robinson M., Stevenson D. et al. Chemotherapy enriches for proinflammatory macrophage phenotypes that support cancer stem-like cells and disease progression in ovarian cancer// Cancer Res. Commun. 2024;4(10):2638-2652. DOI: 10.1158/2767-9764.CRC-24-0311.
21. Gao Z., Ye X., Bordeaux A. et al. miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian cancer stem cells by targeting PTEN// Eur. J. Histochem. 2021;65(1):3186. DOI: 10.4081/ejh.2021.3186.
22. Chen M., Su J., Feng C. et al. Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer// Mol. Med. Rep. 2021;24(3):635. DOI: 10.3892/mmr.2021.12274.
23. Harris K.S., Shi L., Foster B.M. et al. CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance// Sci. Rep. 2021;11(1):1465. DOI: 10.1038/s41598-021-81126-6.
24. Saha S., Parte S., Roy P., Kakar S.S. Ovarian cancer stem cells: characterization and role in tumorigenesis// Adv. Exp. Med. Biol. 2021;1330:151-169. DOI: 10.1007/978-3-030-73359-9_10.
25. Yang L., Yang M., Cui C. et al. The myo-inositol biosynthesis rate-limiting enzyme ISYNA1 suppresses the stemness of ovarian cancer via Notch1 pathway// Cell Signal. 2023;107:110688. DOI: 10.1016/j.cell-sig.2023.110688.
26. Hosseini H., Obradović M.M.S., Hoffmann M. et al. Early dissemination seeds metastasis in breast cancer // Nature. 2016;540(7634):552-558. DOI: 10.1038/nature20785.
27. Luo M., Zeng H., Ma X.Y., Ma X.L. Identification of Hub genes for ovarian cancer stem cell properties with weighted gene co-expression network analysis// Sichuan Da Xue Xue Bao Yi Xue Ban. 2021;52(2):248-258. DOI: 10.12182/20210360205. (In Chinese)
28. Wang C., Zhang C., Yang S. et al. Identification and validation of m5c-related lncRNA risk model for ovarian cancer// J. Ovarian Res. 2023;16(1):96. DOI: 10.1186/s13048-023-01182-6.
29. Uno K., Iyoshi S., Yoshihara M. et al. Metastatic voyage of ovarian cancer cells in ascites with the assistance of various cellular components// Int. J. Mol. Sci. 2022;23(8):4383. DOI: 10.3390/ijms23084383.
30. Markowska A., Kojs Z., Twardawa D. et al. Selected markers of ovarian cancer and their relation to targeted therapy (Review)// Exp. Ther. Med. 2024;27(5):236. DOI: 10.3892/etm.2024.12523.
31. Luo L., Zeng J., Liang B. et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome// Exp. Mol. Pathol. 2011;91(2):596-602. DOI: 10.1016/j.yexmp.2011.06.005.
32. Chung H., Kim Y.H., Kwon M. et al. The effect of salinomycin on ovarian cancer stem-like cells// Obstet. Gynecol. Sci. 2016;59(4):261-268. DOI: 10.5468/ogs.2016.59.4.261.
33. Lee H.G., Shin S.J., Chung H.W. et al. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell// J. Gynecol. Oncol. 2017;28(2):e14. DOI: 10.3802/jgo.2017.28.e14.
34. Wilczyński J.R., Wilczyński M., Paradowska E. Cancer stem cells in ovarian cancer–a source of tumor success and a challenging target for novel therapies// Int. J. Mol. Sci. 2022;23(5):2496. DOI: 10.3390/ijms23052496.
35. Zou M., Yin X., Zhou X. et al. Salinomycin-loaded high-density lipoprotein exerts promising anti-ovarian cancer effects by inhibiting epithelial-mesenchymal transition// Int. J. Nanomedicine. 2022;17:4059-4071. DOI: 10.2147/IJN.S380598.
36. Robinson M., Gilbert S.F., Waters J.A. et al. Characterization of SOX2, OCT4 and NANOG in ovarian cancer tumor-initiating cells// Cancers (Basel). 2021;13(2):262. DOI: 10.3390/cancers13020262.
Review
For citations:
Bulanov D.V., Soloveva A.M. CD117-positive ovarian cancer: a literature review. Journal of Siberian Medical Sciences. 2025;(2):83-96. (In Russ.) https://doi.org/10.31549/2542-1174-2025-9-2-83-96
Views:
12
Email this article 